BIOMARKERS FOR DISEASE BURDEN OF NEUROBLASTOMA

The disclosure relates to monitoring disease and therapy response. More, in particular, the disclosure discloses serum/plasma miRNA. markers for assessment of disease burden in human neuroblastoma. Indeed, the present disclosure discloses that the more the tumor is spread throughout the body, the hi...

Full description

Saved in:
Bibliographic Details
Main Authors DECOCK, Anneleen, MESTDAGH, Pieter, VANDESOMPELE, Joke, ZEKA, Fjoralba
Format Patent
LanguageEnglish
French
German
Published 21.10.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The disclosure relates to monitoring disease and therapy response. More, in particular, the disclosure discloses serum/plasma miRNA. markers for assessment of disease burden in human neuroblastoma. Indeed, the present disclosure discloses that the more the tumor is spread throughout the body, the higher the levels of particular miRNAs in serum/plasma are. Consequently, the latter markers can be used in methods and kits for assessing the neuroblastoma disease burden.
Bibliography:Application Number: EP20180808349